From Teriparatide to Pembrolizumab: CDSCO Clears Import of r-DNA Drugs via CT-18 Route Susmita Roy26 Jan 2026 1:58 PM ISTNew Delhi: The Central Drugs Standard Control Organisation (CDSCO) has granted multiple CT-18 approvals between January 2020 and December 2025 for...
Macleods Gets CDSCO Panel Nod to Conduct BE Studies for Semaglutide Prefilled Pens Susmita Roy25 Jan 2026 11:36 PM ISTNew Delhi: Accepting the toxicity data submitted by Macleods Pharmaceuticals, the Subject Expert Committee (SEC) functioning under the Central Drugs...
Lupin Expands GLP-1 Portfolio with Galenicum Semaglutide Deal sheeba farhat21 Jan 2026 7:01 PM ISTMumbai: Global pharmaceutical major Lupin Limited on Tuesday announced a licensing and supply agreement through its subsidiary Lupin Atlantis Holdings...
Novo Nordisk's Wegovy Gets UK Nod for Higher 7.2 mg Weekly Dose in Obesity Treatment sheeba farhat17 Jan 2026 4:06 PM ISTThe authorisation for the drug, chemically known as semaglutide, covers only patients with a body mass index of 30 or higher using the drug for weight...
Once-Weekly Semaglutide Reduces Insulin Needs in Type 1 Diabetes, Suggests Study Medha Baranwal15 Jan 2026 10:15 AM ISTUSA: In a post hoc analysis of the ADJUST-T1D trial, adults with type 1 diabetes receiving once-weekly semaglutide 1 mg showed a significant reduction...
No Link to Suicidal Thoughts: USFDA Seeks Label Change for Popular Weight-Loss Drugs Wegovy, Zepbound sheeba farhat14 Jan 2026 6:57 PM ISTThe warnings, part of their original approval, were based on reports of such events observed with a variety of older medicines used or studied for...
GLP-1 Use Linked to Improved Survival and Fewer Complications in patients with Diabetes and Cancer: Study Dr. Shravani Dali12 Jan 2026 11:00 AM ISTResearchers have found in a new study that adults with type 2 diabetes and cancer who used GLP-1 receptor agonists had a lower risk of death compared...
Cipla Emerges as Domestic Contender in Anti-Obesity Market with Yurpeak Susmita Roy10 Jan 2026 10:06 PM ISTNew Delhi: India's third-largest drugmaker Cipla has made an early impact in the fast-expanding anti-obesity drug market, with its GLP-1 agonist brand...
Zydus Lifesciences Gets CDSCO Panel Nod to Market Semaglutide Injection for Type 2 Diabetes Susmita Roy9 Jan 2026 11:45 PM ISTNew Delhi: Drug major Zydus Lifesciences Limited has received a key regulatory clearance from the Subject Expert Committee (SEC) functioning under the...
Online Platform Offers India-Sourced Ozempic to US Consumers at Steep Discounts sheeba farhat9 Jan 2026 11:28 PM ISTBengaluru: Online pharmacy platform SaveRxCanada.to said on Wednesday it has begun offering Novo Nordisk's blockbuster diabetes drug, Ozempic,...
Natco Pharma Challenges Novo Nordisk's Wegovy Patent, Reaches Delhi High Court Susmita Roy7 Jan 2026 11:19 PM ISTNew Delhi: Hyderabad-based Natco Pharma has approached the Delhi High Court with a petition seeking revocation of a patent held by Novo Nordisk, the...
Post-Patent Semaglutide Boom: Generics Set for Rs 50,000 Cr Revenue Upside sheeba farhat5 Jan 2026 5:39 PM ISTIn India, the launch of generic semaglutide, expected in the first quarter of FY27, is projected to boost overall Indian Pharmaceutical Market (IPM)...
